GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR POTENTIATES ANTITUMOR-ACTIVITY OF INTERLEUKIN-12 IN MELANOMA MODEL IN MICE

To study the antitumor activity of the combination immunotherapy with interleukin-12 (IL-12) and granulocyte-macrophage colony-stimulating f actor (GM-CSF), a murine MmB 16 melanoma tumor model was used. Seven d ays after inoculation of MmB 16 melanoma cells into the footpad of the right hind limb, mice were treated with IL-12 and/or GM-CSF administe red intratumorally for 7 consecutive days. IL-12 used both at a high(1 mu g) and at a low (0.01 mu g) dose per day produced retardation of t umor growth, although neither treatment resulted in any significant pr olongation of the survival of tumor-bearing mice. GM-CSF did not by it self exert antitumor activity in this model; however, it potentiated a ntitumor effects of IL-12. In particular, survival of tumor-bearing mi ce treated with IL-12 (0.01 mu g per day) and GM-CSF was significantly prolonged compared with that in mice treated with either IL-12 or GM- CSF alone.